Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1999-09-01

AUTHORS

S Carlens, J Aschan, M Remberger, MS Dilber, O Ringdén

ABSTRACT

Low-dose cyclosporine (CsA), starting at 1 mg/kg/day i.v. with early discontinuation, and four doses of methotrexate (MTX), was given to 82 consecutive leukaemic patients receiving HLA-identical sibling marrow transplants. Retrospective controls (n = 40) received CsA, starting at 5–7.5 mg/kg/day i.v., given for 1 year, and MTX. In the low-dose group, the risk of acute GVHD grades I–II was 78% as compared to 57% among the controls (P < 0.01). the risk of acute gvhd grades iii–iv was 2% and 5%, respectively (ns). chronic gvhd occurred in 60% in the low-dose group and 24% in the controls (P < 0.001). extensive chronic gvhd did not differ between the groups (3% vs6%). In multivariate analyses, low-dose CsA was the only factor associated with acute GVHD grades I–IV (P = 0.02). Significant risk factors for chronic GVHD included low-dose CsA (P = 0.002) and CML (P = 0.03). Transplant-related mortality at 3 years post-BMT was 22% and 19%, in the low-dose group and controls, respectively (NS). The probability of relapse was 26% in the low-dose group and 53% in the controls (P = 0.06). In multivariate analysis, high-dose CsA was the strongest risk factor for relapse (P = 0.03). The 3-year relapse-free survival was 58% in the low-dose group and 43% in the controls (P = 0.1). More... »

PAGES

629-635

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bmt.1701954

DOI

http://dx.doi.org/10.1038/sj.bmt.1701954

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1039560833

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10490728


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclosporine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Graft vs Host Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Histocompatibility Testing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.24381.3c", 
          "name": [
            "Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Huddinge, Sweden", 
            "Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carlens", 
        "givenName": "S", 
        "id": "sg:person.0627641241.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627641241.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Huddinge University Hospital, Huddinge, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.24381.3c", 
          "name": [
            "Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Huddinge, Sweden", 
            "Department of Haematology, Huddinge University Hospital, Huddinge, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aschan", 
        "givenName": "J", 
        "id": "sg:person.01030733311.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030733311.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.24381.3c", 
          "name": [
            "Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Remberger", 
        "givenName": "M", 
        "id": "sg:person.0646371511.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646371511.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Huddinge University Hospital, Huddinge, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.24381.3c", 
          "name": [
            "Department of Haematology, Huddinge University Hospital, Huddinge, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dilber", 
        "givenName": "MS", 
        "id": "sg:person.0611503663.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611503663.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.24381.3c", 
          "name": [
            "Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Huddinge, Sweden", 
            "Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ringd\u00e9n", 
        "givenName": "O", 
        "id": "sg:person.01145161711.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145161711.84"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1999-09-01", 
    "datePublishedReg": "1999-09-01", 
    "description": "Low-dose cyclosporine (CsA), starting at 1\u2009mg/kg/day i.v. with early discontinuation, and four doses of methotrexate (MTX), was given to 82 consecutive leukaemic patients receiving HLA-identical sibling marrow transplants. Retrospective controls (n\u2009=\u200940) received CsA, starting at 5\u20137.5\u2009mg/kg/day i.v., given for 1 year, and MTX. In the low-dose group, the risk of acute GVHD grades I\u2013II was 78% as compared to 57% among the controls (P\u2009<\u20090.01). the risk of acute gvhd grades iii\u2013iv was 2% and 5%, respectively (ns). chronic gvhd occurred in 60% in the low-dose group and 24% in the controls (P\u2009<\u20090.001). extensive chronic gvhd did not differ between the groups (3% vs6%). In multivariate analyses, low-dose CsA was the only factor associated with acute GVHD grades I\u2013IV (P\u2009=\u20090.02). Significant risk factors for chronic GVHD included low-dose CsA (P\u2009=\u20090.002) and CML (P\u2009=\u20090.03). Transplant-related mortality at 3 years post-BMT was 22% and 19%, in the low-dose group and controls, respectively (NS). The probability of relapse was 26% in the low-dose group and 53% in the controls (P\u2009=\u20090.06). In multivariate analysis, high-dose CsA was the strongest risk factor for relapse (P\u2009=\u20090.03). The 3-year relapse-free survival was 58% in the low-dose group and 43% in the controls (P\u2009=\u20090.1).", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bmt.1701954", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096890", 
        "issn": [
          "0268-3369", 
          "1476-5365"
        ], 
        "name": "Bone Marrow Transplantation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "keywords": [
      "low-dose group", 
      "low-dose cyclosporine", 
      "low-dose CsA", 
      "chronic GVHD", 
      "acute GVHD", 
      "risk factors", 
      "day i.", 
      "HLA-identical sibling marrow transplants", 
      "multivariate analysis", 
      "acute GVHD grade III", 
      "GVHD grade III", 
      "extensive chronic GVHD", 
      "transplant-related mortality", 
      "high-dose CsA", 
      "marrow transplant recipients", 
      "relapse-free survival", 
      "doses of methotrexate", 
      "significant risk factors", 
      "strong risk factor", 
      "probability of relapse", 
      "risk of relapse", 
      "moderate GVHD", 
      "transplant recipients", 
      "early discontinuation", 
      "leukaemic patients", 
      "marrow transplant", 
      "grade III", 
      "GVHD", 
      "retrospective controls", 
      "relapse", 
      "methotrexate", 
      "only factor", 
      "CsA", 
      "cyclosporine", 
      "short duration", 
      "risk", 
      "group", 
      "discontinuation", 
      "patients", 
      "transplant", 
      "control", 
      "BMT", 
      "leukemia", 
      "years", 
      "mortality", 
      "factors", 
      "doses", 
      "recipients", 
      "CML", 
      "survival", 
      "duration", 
      "i.", 
      "analysis", 
      "probability"
    ], 
    "name": "Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia", 
    "pagination": "629-635", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1039560833"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bmt.1701954"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10490728"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bmt.1701954", 
      "https://app.dimensions.ai/details/publication/pub.1039560833"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:49", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_328.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bmt.1701954"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701954'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701954'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701954'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701954'


 

This table displays all metadata directly associated to this object as RDF triples.

186 TRIPLES      20 PREDICATES      89 URIs      81 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bmt.1701954 schema:about N132e8c575fb04448849fdd66cdd2e2f1
2 N1b9ae22a629a453da86279be497b0c60
3 N49b66eeb833d45509826b6effa253a3d
4 N52343fae178e4107982c80a6582a64e7
5 N7d290f0e1e514620bce0fe2ea467fade
6 N9efc7439e0104a279d4eb799e51e0433
7 Nb9df3971b44a480da16dd6c087d4ecee
8 Nbaaa8c40af094049ae342f0f0e367e5a
9 Ncfa50b8f9ab4453e836418c5e3612685
10 Nd766b965cd1b4a23b1625731ecd0e7ff
11 anzsrc-for:11
12 anzsrc-for:1117
13 schema:author Na17b8c84e94f49948921d178cd8d5b8f
14 schema:datePublished 1999-09-01
15 schema:datePublishedReg 1999-09-01
16 schema:description Low-dose cyclosporine (CsA), starting at 1 mg/kg/day i.v. with early discontinuation, and four doses of methotrexate (MTX), was given to 82 consecutive leukaemic patients receiving HLA-identical sibling marrow transplants. Retrospective controls (n = 40) received CsA, starting at 5–7.5 mg/kg/day i.v., given for 1 year, and MTX. In the low-dose group, the risk of acute GVHD grades I–II was 78% as compared to 57% among the controls (P < 0.01). the risk of acute gvhd grades iii–iv was 2% and 5%, respectively (ns). chronic gvhd occurred in 60% in the low-dose group and 24% in the controls (P < 0.001). extensive chronic gvhd did not differ between the groups (3% vs6%). In multivariate analyses, low-dose CsA was the only factor associated with acute GVHD grades I–IV (P = 0.02). Significant risk factors for chronic GVHD included low-dose CsA (P = 0.002) and CML (P = 0.03). Transplant-related mortality at 3 years post-BMT was 22% and 19%, in the low-dose group and controls, respectively (NS). The probability of relapse was 26% in the low-dose group and 53% in the controls (P = 0.06). In multivariate analysis, high-dose CsA was the strongest risk factor for relapse (P = 0.03). The 3-year relapse-free survival was 58% in the low-dose group and 43% in the controls (P = 0.1).
17 schema:genre article
18 schema:isAccessibleForFree false
19 schema:isPartOf Na4f10d2df2dc441789fccd7e9c3e82ab
20 Nf46e3ce711144395867317c14a3a1203
21 sg:journal.1096890
22 schema:keywords BMT
23 CML
24 CsA
25 GVHD
26 GVHD grade III
27 HLA-identical sibling marrow transplants
28 acute GVHD
29 acute GVHD grade III
30 analysis
31 chronic GVHD
32 control
33 cyclosporine
34 day i.
35 discontinuation
36 doses
37 doses of methotrexate
38 duration
39 early discontinuation
40 extensive chronic GVHD
41 factors
42 grade III
43 group
44 high-dose CsA
45 i.
46 leukaemic patients
47 leukemia
48 low-dose CsA
49 low-dose cyclosporine
50 low-dose group
51 marrow transplant
52 marrow transplant recipients
53 methotrexate
54 moderate GVHD
55 mortality
56 multivariate analysis
57 only factor
58 patients
59 probability
60 probability of relapse
61 recipients
62 relapse
63 relapse-free survival
64 retrospective controls
65 risk
66 risk factors
67 risk of relapse
68 short duration
69 significant risk factors
70 strong risk factor
71 survival
72 transplant
73 transplant recipients
74 transplant-related mortality
75 years
76 schema:name Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia
77 schema:pagination 629-635
78 schema:productId N447e2c1c46584000aa6131c3d103ea47
79 N68652241f0b04975b10b815fd27d62fd
80 N73f46c5763ec41b1b7408a2a157636e0
81 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039560833
82 https://doi.org/10.1038/sj.bmt.1701954
83 schema:sdDatePublished 2022-11-24T20:49
84 schema:sdLicense https://scigraph.springernature.com/explorer/license/
85 schema:sdPublisher Nbe592cef768a45a1b4fe53dc5bce065f
86 schema:url https://doi.org/10.1038/sj.bmt.1701954
87 sgo:license sg:explorer/license/
88 sgo:sdDataset articles
89 rdf:type schema:ScholarlyArticle
90 N132e8c575fb04448849fdd66cdd2e2f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Bone Marrow Transplantation
92 rdf:type schema:DefinedTerm
93 N1b9ae22a629a453da86279be497b0c60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Leukemia
95 rdf:type schema:DefinedTerm
96 N447e2c1c46584000aa6131c3d103ea47 schema:name dimensions_id
97 schema:value pub.1039560833
98 rdf:type schema:PropertyValue
99 N49b66eeb833d45509826b6effa253a3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Cyclosporine
101 rdf:type schema:DefinedTerm
102 N507e33edade945afa4c46d3db886bb07 rdf:first sg:person.01145161711.84
103 rdf:rest rdf:nil
104 N52343fae178e4107982c80a6582a64e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Histocompatibility Testing
106 rdf:type schema:DefinedTerm
107 N68652241f0b04975b10b815fd27d62fd schema:name doi
108 schema:value 10.1038/sj.bmt.1701954
109 rdf:type schema:PropertyValue
110 N73f46c5763ec41b1b7408a2a157636e0 schema:name pubmed_id
111 schema:value 10490728
112 rdf:type schema:PropertyValue
113 N78dafa0fd3c74f2ea0ddb2914ec4ebea rdf:first sg:person.01030733311.14
114 rdf:rest Ncbcf08ac075347159f3e7df96a84f0e1
115 N7d290f0e1e514620bce0fe2ea467fade schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Humans
117 rdf:type schema:DefinedTerm
118 N9dc8cb4fb0304c3dac3632ef652aa9b5 rdf:first sg:person.0611503663.38
119 rdf:rest N507e33edade945afa4c46d3db886bb07
120 N9efc7439e0104a279d4eb799e51e0433 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Recurrence
122 rdf:type schema:DefinedTerm
123 Na17b8c84e94f49948921d178cd8d5b8f rdf:first sg:person.0627641241.94
124 rdf:rest N78dafa0fd3c74f2ea0ddb2914ec4ebea
125 Na4f10d2df2dc441789fccd7e9c3e82ab schema:volumeNumber 24
126 rdf:type schema:PublicationVolume
127 Nb9df3971b44a480da16dd6c087d4ecee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Time Factors
129 rdf:type schema:DefinedTerm
130 Nbaaa8c40af094049ae342f0f0e367e5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Risk
132 rdf:type schema:DefinedTerm
133 Nbe592cef768a45a1b4fe53dc5bce065f schema:name Springer Nature - SN SciGraph project
134 rdf:type schema:Organization
135 Ncbcf08ac075347159f3e7df96a84f0e1 rdf:first sg:person.0646371511.36
136 rdf:rest N9dc8cb4fb0304c3dac3632ef652aa9b5
137 Ncfa50b8f9ab4453e836418c5e3612685 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Disease-Free Survival
139 rdf:type schema:DefinedTerm
140 Nd766b965cd1b4a23b1625731ecd0e7ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Graft vs Host Disease
142 rdf:type schema:DefinedTerm
143 Nf46e3ce711144395867317c14a3a1203 schema:issueNumber 6
144 rdf:type schema:PublicationIssue
145 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
146 schema:name Medical and Health Sciences
147 rdf:type schema:DefinedTerm
148 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
149 schema:name Public Health and Health Services
150 rdf:type schema:DefinedTerm
151 sg:journal.1096890 schema:issn 0268-3369
152 1476-5365
153 schema:name Bone Marrow Transplantation
154 schema:publisher Springer Nature
155 rdf:type schema:Periodical
156 sg:person.01030733311.14 schema:affiliation grid-institutes:grid.24381.3c
157 schema:familyName Aschan
158 schema:givenName J
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030733311.14
160 rdf:type schema:Person
161 sg:person.01145161711.84 schema:affiliation grid-institutes:grid.24381.3c
162 schema:familyName Ringdén
163 schema:givenName O
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145161711.84
165 rdf:type schema:Person
166 sg:person.0611503663.38 schema:affiliation grid-institutes:grid.24381.3c
167 schema:familyName Dilber
168 schema:givenName MS
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611503663.38
170 rdf:type schema:Person
171 sg:person.0627641241.94 schema:affiliation grid-institutes:grid.24381.3c
172 schema:familyName Carlens
173 schema:givenName S
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627641241.94
175 rdf:type schema:Person
176 sg:person.0646371511.36 schema:affiliation grid-institutes:grid.24381.3c
177 schema:familyName Remberger
178 schema:givenName M
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646371511.36
180 rdf:type schema:Person
181 grid-institutes:grid.24381.3c schema:alternateName Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden
182 Department of Haematology, Huddinge University Hospital, Huddinge, Sweden
183 schema:name Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Huddinge, Sweden
184 Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden
185 Department of Haematology, Huddinge University Hospital, Huddinge, Sweden
186 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...